Economics of hematopoietic cell transplantation.
暂无分享,去创建一个
[1] J. Pidala,et al. Practice variation in physician referral for allogeneic hematopoietic cell transplantation , 2012, Bone Marrow Transplantation.
[2] N. Majhail,et al. Costs and cost-effectiveness of hematopoietic cell transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] W. Baine,et al. The Agency for Healthcare Research and Quality , 2006, Italian Journal of Public Health.
[4] G. Ruiz-Argüelles,et al. A Mexican way to cope with stem cell grafting , 2012, Hematology.
[5] M. Postma,et al. Cost Benefit and Cost Effectiveness of Antifungal Prophylaxis in Immunocompromised Patients Treated for Haematological Malignancies , 2011, PharmacoEconomics.
[6] David C. Miller,et al. Large variations in Medicare payments for surgery highlight savings potential from bundled payment programs. , 2011, Health affairs.
[7] Karol Sikora,et al. Delivering affordable cancer care in high-income countries. , 2011, The Lancet. Oncology.
[8] M. Porter,et al. The Big Idea : How to Solve the Cost Crisis in Health Care , 2012 .
[9] W. Leisenring,et al. Factors associated with adherence to preventive care practices among hematopoietic cell transplantation survivors. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] Thomas J. Smith,et al. Bending the cost curve in cancer care. , 2011, The New England journal of medicine.
[11] S. Ramsey,et al. Cancer diagnosis as a risk factor for personal bankruptcy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Eric J Feuer,et al. Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.
[13] Xianglin L. Du,et al. The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] Y. Lubell,et al. A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand , 2010, BMC health services research.
[15] J. Rowland,et al. Forgoing medical care because of cost , 2010, Cancer.
[16] J. Wagner,et al. Costs of pediatric allogeneic hematopoietic‐cell transplantation , 2010, Pediatric blood & cancer.
[17] M. Roizen. Cost sharing and the initiation of drug therapy for the chronically ill , 2010 .
[18] D. Weisdorf,et al. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[19] M. Solomon,et al. Cost sharing and the initiation of drug therapy for the chronically ill. , 2009, Archives of internal medicine.
[20] Micah B. Hartman,et al. National health spending in 2007: slower drug spending contributes to lowest rate of overall growth since 1998. , 2009, Health affairs.
[21] Spyridon S Marinopoulos,et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. , 2008, Journal of clinical epidemiology.
[22] S. Giralt,et al. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? , 2008, Bone Marrow Transplantation.
[23] D. Zahrieh,et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[24] L. Breitscheidel. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia , 2008, Journal of medical economics.
[25] J. Brophy,et al. The cost-effectiveness of stem cell transplantations from unrelated donors in adult patients with acute leukemia. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[26] D. Zahrieh,et al. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy , 2007, Bone Marrow Transplantation.
[27] B. Friedman,et al. Procedures with the Most Rapidly Increasing Hospital Costs, 2000–2004 , 2007 .
[28] J. Gajewski,et al. Do affluent societies have the only options for the best therapy? , 2007, Leukemia.
[29] A. Gratwohl,et al. Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe—Impact of cost considerations , 2007, Leukemia.
[30] Christopher S Hollenbeak,et al. Using comorbidity indexes to predict costs for head and neck cancer. , 2007, Archives of otolaryngology--head & neck surgery.
[31] M. Remberger,et al. Costs of Allogeneic Hematopoietic Stem Cell Transplantation , 2006 .
[32] M. Remberger,et al. Treatment Costs and Survival in Patients with Grades III-IV Acute Graft-Versus-Host Disease after Allogenic Hematopoietic Stem Cell Transplantation During Three Decades , 2006, Transplantation.
[33] M. Remberger,et al. Costs of allogeneic hematopoietic stem cell transplantation. , 2006, Transplantation.
[34] I. Durand-zaleski,et al. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia , 2005, Bone Marrow Transplantation.
[35] D. Weisdorf,et al. Economic analysis of unrelated allogeneic bone marrow transplantation: results from the randomized clinical trial of T-cell depletion vs unmanipulated grafts for the prevention of graft-versus-host disease , 2005, Bone Marrow Transplantation.
[36] G. Skrepnek,et al. Cost‐Efficacy of Imatinib versus Allogeneic Bone Marrow Transplantation with a Matched Unrelated Donor in the Treatment of Chronic Myelogenous Leukemia: A Decision‐Analytic Approach , 2005, Pharmacotherapy.
[37] A. Hagenbeek,et al. Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma. , 2005, Haematologica.
[38] R. Storb,et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. , 2004, Blood.
[39] S. Chevret,et al. PREDICTING THE COSTS OF ALLOGENEIC SIBLING STEM-CELL TRANSPLANTATION: RESULTS FROM A PROSPECTIVE, MULTICENTER, FRENCH STUDY , 2004, Transplantation.
[40] C. Pashos,et al. Economic burden of acute myeloid leukemia: a literature review. , 2004, Cancer treatment reviews.
[41] R. Kaplan,et al. Time-driven activity-based costing. , 2003, Harvard business review.
[42] Robert S. Kaplan,et al. Tool kit: Time-driven activity-based costing , 2004 .
[43] C. Tom Kouroukis,et al. Cost-effectiveness of a Transplantation Strategy Compared to Melphalan and Prednisone in Younger Patients with Multiple Myeloma , 2003, Leukemia & lymphoma.
[44] M. Remberger,et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. , 2002, Blood.
[45] C. Bennett,et al. Lack of caregivers limits use of outpatient hematopoietic stem cell transplant program , 2002, Bone Marrow Transplantation.
[46] D. Zahrieh,et al. Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. , 2002, Blood.
[47] A. Hagenbeek,et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia , 2002, Bone Marrow Transplantation.
[48] G. Anderson,et al. Out-of-pocket medical spending for care of chronic conditions. , 2001, Health affairs.
[49] T. Brennan,et al. The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer. , 2001, Health affairs.
[50] F. Spijkervet,et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] J. Weeks,et al. Predicting costs of stem-cell transplantation. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] E. Bass,et al. Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] M. Bishop,et al. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation , 1999, Bone Marrow Transplantation.
[54] F. Locatelli,et al. Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia , 1999, Bone Marrow Transplantation.
[55] G. Dranitsaris,et al. Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective , 1998, Bone Marrow Transplantation.
[56] K. Kuntz,et al. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. , 1998, Blood.
[57] K. Sobocinski,et al. Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know? , 1998, Bone Marrow Transplantation.
[58] S Meiman,et al. A detailed analysis of charges for hematopoietic stem cell transplantation at a children’s hospital , 1998, Bone Marrow Transplantation.
[59] Wiklund Ra,et al. First of two parts , 1997 .
[60] T. Bodenheimer. The Oregon Health Plan--lessons for the nation. Second of two parts. , 1997, The New England journal of medicine.
[61] N. Schmitz,et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] T. Bodenheimer. The Oregon Health Plan--lessons for the nation. First of two parts. , 1997, The New England journal of medicine.
[63] M. Gold. Cost-effectiveness in health and medicine , 2016 .
[64] T O Jefferson,et al. Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.
[65] D. Feeny,et al. Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] P. Bierman,et al. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] S. Goodman,et al. Factors influencing third party payer costs for allogeneic BMT. , 1993, Bone marrow transplantation.
[68] J. Reiffers,et al. Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. , 1992, Bone marrow transplantation.
[69] A S Detsky,et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[70] H. Welch,et al. Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. , 1989, The New England journal of medicine.
[71] D. Himmelstein,et al. Transplanted technology: Third World options and First World science. , 1987, The New England journal of medicine.